Legend Biotech Corporation American Depositary Shares (LEGN)
Stock · NASDAQ · Health Care
$18.45as of 10/16/2026
Price chart
Active signals
Resistance level
$18.75
Industry
Biotechnology: Pharmaceutical Preparations
LEGN Signal Track Record
How signals performed across all stocks →What LEGN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | -2.4% | 38% | September 11, 2026 |
| Bollinger Band Breakdown | 26 | +1.9% | 54% | September 10, 2026 |
| Bollinger Band Breakout | 18 | -3.7% | 44% | June 2, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -6.1% | 31% | September 18, 2025 |
| Any 20-session window (baseline) | -3.0% | 40% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LEGN
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). Th…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 3,200
- Website
- investors.legendbiotech.com/
Fundamentals
- 1-day range
- $18.85$19.92
- Market cap
- $3.58B
- P/E (trailing)
- —
- P/E (forward)
- 18.86
- EPS (trailing)
- $-0.25
- Dividend yield
- —
- Beta
- 0.57
- Avg. volume
- 2.34M
52-week range
$16.24$37.5
Next earnings: November 11, 2026 · EPS estimate $0.01Before Openconfirmed
Forecasts
13 analyst ratings
Buy 74%
Hold 26%
Sell 0%
1-year price forecast
High
$68
+268.6%
Median
$48
+160.2%
Low
$24
+30.1%
Legend Biotech Corporation American Depositary Shares Competitors
Chosen by industry and closest market cap.
- LEGNLegend Biotech Corporation American Depositary Shares$18.48▼ 6.67%Market cap $3.58BP/E —$16.24$37.5
- RCUSArcus Biosciences Inc. Common Stock$22.12▼ 3.07%Market cap $3.56BP/E —$15.38$31.74
- TLXTelix Pharmaceuticals Limited American Depositary Shares$10.69▲ 1.14%Market cap $3.60BP/E —$6.28$13.11
- ALMSAlumis Inc. Common Stock$6.12▼ 3.01%Market cap $3.54BP/E —$4.37$31.35
- IDYAIDEAYA Biosciences Inc. Common Stock$32.85▼ 2.95%Market cap $3.50BP/E —$26.44$42.68
- ELVNEnliven Therapeutics Inc. Common Stock$37.32▼ 5.11%Market cap $3.67BP/E —$14.79$62.32
- GPCRStructure Therapeutics Inc. American Depositary Shares$21.08▼ 5.00%Market cap $3.74BP/E —$25.59$94.9
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LEGN Legend Biotech Corporation American Depositary Shares | $3.58B | — | $18.48 | ▼ 6.67% | $16.24$37.5 |
| RCUS Arcus Biosciences Inc. Common Stock | $3.56B | — | $22.12 | ▼ 3.07% | $15.38$31.74 |
| TLX Telix Pharmaceuticals Limited American Depositary Shares | $3.60B | — | $10.69 | ▲ 1.14% | $6.28$13.11 |
| ALMS Alumis Inc. Common Stock | $3.54B | — | $6.12 | ▼ 3.01% | $4.37$31.35 |
| IDYA IDEAYA Biosciences Inc. Common Stock | $3.50B | — | $32.85 | ▼ 2.95% | $26.44$42.68 |
| ELVN Enliven Therapeutics Inc. Common Stock | $3.67B | — | $37.32 | ▼ 5.11% | $14.79$62.32 |
| GPCR Structure Therapeutics Inc. American Depositary Shares | $3.74B | — | $21.08 | ▼ 5.00% | $25.59$94.9 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Legend Biotech Says FDA Cleared In Vivo CAR-T Therapy LB2501 For U.S. Phase 1/2 Trial In B-Cell Cancersbenzinga · 10/15/2026
- JP Morgan Maintains Neutral on Legend Biotech, Lowers Price Target to $33Benzinga · 10/9/2026
- RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $56Benzinga · 10/8/2026
- Legend Biotech (LEGN) Tests Its Valuation After Fresh CARVYKTI Five Year DataYahoo · 10/4/2026
- Sector Update: Healthcare Stocks Steady Late AfternoonYahoo · 10/2/2026
- Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS SaysYahoo · 10/2/2026
- Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple MyelomaYahoo · 10/1/2026
- HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price TargetBenzinga · 9/30/2026
- Asian Equities Traded in the US as American Depositary Receipts Decline in Tuesday TradingYahoo · 9/29/2026
Insider Activity
Insider Actions →Acquired
1.30M
Disposed
42.2K
- Corazon (Corsee) D. Sanders · September 29, 2026 · Sale27.4K @ $9.46
- Mao Li · September 24, 2026 · Grant21.0K
- Salovey Peter · September 24, 2026 · Grant28.3K
- Casey Patrick John · September 24, 2026 · Grant21.0K
- Ji Darren Xiaohui · September 24, 2026 · Grant28.3K
- Tomas J. Heyman · September 24, 2026 · Grant21.0K
- Corazon (Corsee) D. Sanders · September 24, 2026 · Grant21.0K
- Santos Carlos E · September 21, 2026 · Sale5.4K @ $9.14
- Santos Carlos E · September 21, 2026 · Grant19.7K
- Ingrid Zhang · September 15, 2026 · Grant1.13M
- BASH ALAN · August 14, 2026 · Grant4.9K
- Casey Patrick John · June 30, 2026 · Sale6.0K @ $14.8
- Huang Ying · June 30, 2026 · Gift3.4K
Institutional Ownership
March 31, 2026
- Total shares held
- 96.59M
- Total value held
- $1.70B
- Institutional holders
- 188
Top holders this quarter
- Unknown25.70M
- Unknown7.69M
- Unknown7.58M
- Unknown5.98M
- Unknown5.76M
- Unknown4.68M
- Unknown3.89M
- Unknown2.30M
- Unknown2.25M
- Unknown1.89M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Legend Biotech Faces Revised Valuation After CARVYKTI Data
Legend Biotech’s valuation is under review after the release of five‑year CARVYKTI data. JP Morgan and RBC Capital both lowered their price targets to $33 and $56 respectively, signaling a more cautious outlook. The stock is near its 52‑week low and currently tests support at $18.75, adding pressure to the revised targets.
Legend Biotech Faces Revised Valuation After CARVYKTI Data. Legend Biotech’s valuation is under review after the release of five‑year CARVYKTI data. JP Morgan and RBC Capital both lowered their price targets to $33 and $56 respectively, signaling a more cautious outlook. The stock is near its 52‑week low and currently tests support at $18.75, adding pressure to the revised targets.